Johnson and Johnson

2026. g. 26. sept. 00:01 UTC

Johnson & Johnson's TREMFYA® met endpoints in the Phase 4 STAR study, but the stock is trading lower in after-market hours amid routine fluctuations.

2026. g. 25. sept. 20:07 UTC

Johnson & Johnson's stock rose after positive Phase 4 STAR study results for Tremfya and encouraging long-term data for CARVYKTI in multiple myeloma patients.

2026. g. 24. sept. 23:01 UTC

Johnson & Johnson's shares are advancing in after-market trading, holding a roughly flat position since Thursday's close amid limited fluctuations.

2026. g. 23. sept. 23:05 UTC

Johnson & Johnson is experiencing a slight decline in after-market trading, reflecting a cumulative return near the lower end of its one-month trading range.

2026. g. 22. sept. 20:07 UTC

Johnson & Johnson shares fell following a slight decline from Monday's close, despite bullish social media sentiment and positive Phase 3 study results for CAPLYTA®.

2026. g. 21. sept. 20:06 UTC

Johnson & Johnson's stock is declining today despite receiving EU approval for ICOTYDE, a new treatment for plaque psoriasis, and positive Phase 3 results for Caplyta.

2026. g. 18. sept. 23:01 UTC

Johnson & Johnson's shares advanced modestly in after-market trading, continuing positive momentum following five consecutive sessions that ended higher.

2026. g. 17. sept. 23:06 UTC

Johnson & Johnson is trading slightly higher in after-market hours, continuing a trend of five consecutive sessions finishing higher since Thursday's close.

2026. g. 16. sept. 23:06 UTC

Johnson & Johnson's shares are trading lower in after-market hours, briefly dipping to a low while remaining below their 20-day moving average.

2026. g. 15. sept. 23:01 UTC

Johnson & Johnson shares are lower in after-market trading amid negative market sentiment following a sharp decline in the New York Empire State Manufacturing Index.

2026. g. 14. sept. 23:06 UTC

Johnson & Johnson shares rose in after-market trading following the final survival analysis results of the Phase 3 PAPILLON study for RYBREVANT and chemotherapy.

2026. g. 12. sept. 00:01 UTC

Johnson & Johnson shares rose in after-hours trading amid reports of Apollo Global Management discussing a $20 billion acquisition of its DePuy Synthes unit.

2026. g. 11. sept. 23:41 UTC

Johnson & Johnson shares higher after news of Apollo Global Management's interest in acquiring its $20 billion orthopedics unit, DePuy Synthes.

2026. g. 10. sept. 20:07 UTC

Johnson & Johnson shares are lower despite receiving CE Marking for its ACUVUE OASYS MAX 2-Week lens, with HSBC raising its price target to $320.

2026. g. 9. sept. 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting a modest increase since Wednesday's close despite three consecutive sessions of declines.

2026. g. 8. sept. 20:02 UTC

Johnson & Johnson shares are lower today amid declines in the Pharmaceuticals sub-sector, despite strong merger and acquisition capacity estimated at $80 billion.

2026. g. 5. sept. 00:01 UTC

Johnson & Johnson shares are higher in after-market trading, with no specific news driving the move. The stock reached a session high earlier today.

2026. g. 4. sept. 20:08 UTC

Shares of Johnson & Johnson are lower as Timothy Schmid exercised stock options for 33,597 shares valued at approximately $4.39 million.

2026. g. 3. sept. 23:41 UTC

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

2026. g. 2. sept. 23:06 UTC

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

2026. g. 1. sept. 20:01 UTC

Johnson & Johnson shares are higher today, reaching the upper end of their one-month trading range during the session. No specific news was identified.

2026. g. 31. aug. 23:06 UTC

Johnson & Johnson shares are higher in after-market trading following the announcement of an investor conference call on October 13, 2026, for third-quarter results.

2026. g. 29. aug. 00:01 UTC

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

2026. g. 28. aug. 20:08 UTC

Johnson & Johnson shares are higher during Friday's session, reflecting a modest gain since Thursday's close amid routine trading and rising Treasury yields.

2026. g. 27. aug. 23:01 UTC

Johnson & Johnson shares advanced in after-market trading, recovering from earlier volatility. Broader market context includes a decline in initial jobless claims.

2026. g. 26. aug. 23:06 UTC

Johnson & Johnson shares are lower during after-market hours, reflecting a decline since Wednesday's close amid broader market concerns over persistent inflation pressures.

2026. g. 25. aug. 23:06 UTC

Johnson & Johnson shares are lower in after-market trading, reflecting broader market trends and a decline in crude oil prices influencing investor sentiment.

2026. g. 24. aug. 19:06 UTC

Johnson & Johnson's shares are higher today, recovering from earlier volatility and trading above its 20-day moving average near a one-month peak.

2026. g. 21. aug. 23:06 UTC

Johnson & Johnson shares are higher in after-hours trading, maintaining a position above the 20-day moving average despite a slight pullback from earlier gains.

2026. g. 20. aug. 23:41 UTC

Johnson & Johnson shares are higher in after-market trading following operational sales growth and a raised full-year outlook amid recent FDA clearances for its bronchoscopy software.